Cited by 400Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchNF-κB Signaling Pathways

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR

Open access

Bivona, Trever G., Hieronymus, Haley, Parker, Joel, Chang, Kenneth, Taron, Miquel, Rosell, Rafael, Moonsamy, Philicia, Dahlman, Kimberly, Miller, Vincent A., Costa, Carlota, Hannon, Gregory, Sawyers, Charles L.·2011·Nature

DOI 10.1038/nature09870PMC PMC3541675

Open this paper in CoChat — free account

Abstract

Human lung adenocarcinomas with activating mutations in EGFR (epidermal growth factor receptor) often respond to treatment with EGFR tyrosine kinase inhibitors (TKIs), but the magnitude of tumour regression is variable and transient. This heterogeneity in treatment response could result from genetic modifiers that regulate the degree to which tumour cells are dependent on mutant EGFR. Through a pooled RNA interference screen, we show that knockdown of FAS and several components of the NF-κB pathway specifically enhanced cell death induced by the EGFR TKI erlotinib in EGFR-mutant lung cancer cells. Activation of NF-κB through overexpression of c-FLIP or IKK (also known as CFLAR and IKBKB, respectively), or silencing of IκB (also known as NFKBIA), rescued EGFR-mutant lung cancer cells from EGFR TKI treatment. Genetic or pharmacologic inhibition of NF-κB enhanced erlotinib-induced apoptosis in erlotinib-sensitive and erlotinib-resistant EGFR-mutant lung cancer models. Increased expression of the NF-κB inhibitor IκB predicted for improved response and survival in EGFR-mutant lung cancer patients treated with EGFR TKI. These data identify NF-κB as a potential companion drug target, together with EGFR, in EGFR-mutant lung cancers and provide insight into the mechanisms by which tumour cells escape from oncogene dependence.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature09870

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citation
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Self-citation
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598
Self-citation
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Self-citation
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059
IKK/NF- B signaling: balancing life and death - a new approach to cancer therapy
Luo, J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26322 · Cited by 898
Oncogene Addiction
Weinstein, I. B., & Joe, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3293 · Cited by 805
Targeting the cancer kinome through polypharmacology
Knight, Z. A., Lin, H., & Shokat, K. M. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2787 · Cited by 674
Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma
Meylan, E., Dooley, A. L., Feldser, D. M., Shen, L., Turk, E., Ouyang, C., & Jacks, T. (2009) · Nature · doi:10.1038/nature08462 · Cited by 514

Show all 24 references

Sorted by citations

Items 301–400 of 400

NF-κB-Dependent and -Independent (Moonlighting) IκBα Functions in Differentiation and Cancer
Espinosa, L., & Marruecos, L. (2021) · Biomedicines · doi:10.3390/biomedicines9091278 · Cited by 10
EGFR Mutant Lung Cancer
Gong, Y., & Pao, W. J. (2011) · Current topics in microbiology and immunology · doi:10.1007/82_2011_171 · Cited by 10
Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer
Velázquez, A. I., & McCoach, C. E. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.08.31 · Cited by 9
Computational Analysis of Drug Resistance Network in Lung Adenocarcinoma
Kara, A., Özgür, A., Teki̇n, Ş., & Tutar, Y. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210218175439 · Cited by 9
[Research progress of the resistance mechanism of non-small cell lung cancer to EGFR-TKIs].
Liu, H., Wang, M., Hu, K., Xu, Y., Ma, M., Zhong, W., Zhao, J., Li, L., & Wang, H. (2013) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2013.10.07 · Cited by 9
Sortilin as a new membrane inhibitor of EGFR trafficking for overcoming resistance to EGFR inhibitors in non-small cell lung cancer
Li, Q., Ma, W., & Li, T. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.08.25 · Cited by 9
The molecular features of lung cancer stem cells in dedifferentiation process-driven epigenetic alterations
Masciale, V., Banchelli, F., Grisendi, G., Samarelli, A. V., Raineri, G., Rossi, T., Zanoni, M., Cortesi, M., Bandini, S., Ulivi, P., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107994 · Cited by 11
From targeted therapy to a novel way: Immunogenic cell death in lung cancer
Xu, J., Xiong, Y., Xu, Z., Xing, H., Zhou, L., & Zhang, X. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1102550 · Cited by 10
Systematic bioinformatic approaches reveal novel gene expression signatures associated with acquired resistance to EGFR targeted therapy in lung cancer
Naeini, M. M., Tavassoli, M., & Ghaedi, K. (2018) · Gene · doi:10.1016/j.gene.2018.04.077 · Cited by 8
Esculetin Attenuates the Growth of Lung Cancer by Downregulating Wnt Targeted Genes and Suppressing NF-κB
Zhu, X., Gu, J., & Qian, H. (2018) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2017.09.012 · Cited by 8
Transglutaminase 2 Induces Intrinsic EGFR-TKI Resistance in NSCLC Harboring EGFR Sensitive MutationsPreprint
Choi, J., Yoon, S., Kim, D., Moon, Y. W., Lee, C. H., Seo, S., Cheon, J., Gho, Y. S., Kim, C., Lee, E. R., et al. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.3379807 · Cited by 8
Canonical NF-κB Promotes Lung Epithelial Cell Tumour Growth by Downregulating the Metastasis Suppressor CD82 and Enhancing Epithelial-to-Mesenchymal Cell Transition
Roupakia, E., Chavdoula, E., Karpathiou, G., Vatsellas, G., Chatzopoulos, D., Mela, A., Gillette, J. M., Kriegsmann, K., Kriegsmann, M., Batistatou, A. K., et al. (2021) · Cancers · doi:10.3390/cancers13174302 · Cited by 6
Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance
Mahfoudhi, E., Ricordel, C., Lécuyer, G., Mouric, C., Léna, H., & Pedeux, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.853501 · Cited by 7
Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond
Mitsudomi, T., & Suda, K. (2013) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s49603 · Cited by 6
Comparative Analysis of Transcriptomic and Proteomic Expression between Two Non-Small Cell Lung Cancer Subtypes
Nicholas, B., Bailey, A. G., McCann, K. J., Johnson, P., Elliott, T. J., Ottensmeier, C. H. H., & Skipp, P. J. S. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00773 · Cited by 5
Genomic Profiling on an Unselected Solid Tumor Population Reveals a Highly Mutated Wnt/β-Catenin Pathway Associated with Oncogenic EGFR Mutations
Jiang, J., Protopopov, A. I., Sun, R., Lyle, S. R., & Russell, M. K. (2018) · Journal of Personalized Medicine · doi:10.3390/jpm8020013 · Cited by 5
Role of YES1 amplification in EGFR mutation‐positive non‐small cell lung cancer: Primary resistance to afatinib in a patient
Tao, J., Sun, D., & Hou, H. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13583 · Cited by 5
The lysosome as a novel therapeutic target of EGFR-mediated tumor inflammation
Sung, W. J., Kim, D., Zhu, A., Cho, N., Yoo, H. M., Noh, J. H., Kim, K. M., Lee, H., & Hong, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1050758 · Cited by 5
Development of triazole-based PKC-inhibitors to overcome resistance to EGFR inhibitors in EGFR-mutant lung cancers.
Lee, P., Kumar, V., Sivakumar, G., Tseng, T.-Y., Li, Y., Jiang, Y.-C., Hsiao, Y., Lin, H., Chang, C., & Hung, M. (2023) · PubMed Central · Cited by 5
Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis
Miyagi, M., Katagiri, H., Murata, H., Wasa, J., Takahashi, T., Murakami, H., Harada, H., Mori, K. P., & Takahashi, M. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-02226-1 · Cited by 5
Intact-cell MALDI-ToF mass spectrometry for the authentication of drug-adapted cancer cell lines
Povey, J. F., Saintas, E., Aderemi, A. V., Rothweiler, F., Zehner, R., Dirks, W. G., Cinatl, J., Racher, A. J., Wass, M. N., Smales, C. M., et al. (2019) · Cells · doi:10.3390/cells8101194 · Cited by 5
Ligation of CM1 enhances apoptosis of lung cancer cells through different mechanisms in conformity with EGFR mutation
Lee, H.-K., Park, G. B., Kim, Y. S., Song, H., Broaddus, V. C., & Hur, D. Y. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1731 · Cited by 5
EGFR Inhibitors as Therapeutic Agents in Head and Neck Cancer
Liu, H., Cracchiolo, J. R., Beck, T. N., Serebriiskii, I. G., & Golemis, E. A. (2014) · Springer eBooks · doi:10.1007/978-1-4614-8815-6_4 · Cited by 4
Overcoming Tyrosine Kinase Inhibitor Resistance in Transformed Cell Harboring SEPT9-ABL1 Chimeric Fusion Protein
Kawai, H., Matsushita, H., Suzuki, R., Kitamura, Y., Ogawa, Y., Kawada, H., & Ando, K. (2019) · Neoplasia · doi:10.1016/j.neo.2019.06.001 · Cited by 4
Exosome, an important transmitter in the drug resistance of non-small cell lung cancer
Ji, H., Zhang, L., & Ye, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1539047 · Cited by 3
Exosome-mediated crosstalk between immune cells and tumor microenvironment in lung cancer: Implications for immune evasion and therapeutic resistance
Tang, R., Juan, Z., Xing, F., Yi, Z., & Fu, Y. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112452 · Cited by 3
A phase i study of ixazomib and erlotinib in patients with advanced solid tumors
Kato, S., Adashek, J. J., Subbiah, V., Fu, S., Sun, M., Nguyen, L. M., Brown, E. J., Yap, T. A., Karp, D. D., Piha-Paul, S. A., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01153-y · Cited by 4
Molecular targets in cancer therapy
Kummar, S., & Doroshow, J. H. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.170 · Cited by 3
ALK inhibitors downregulate the expression of death receptor 4 in ALK-mutant lung cancer cells via facilitating Fra-1 and c-Jun degradation and subsequent AP-1 suppression
Zhao, W., Yu, D., Zhai, Y., & Sun, S. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100908 · Cited by 3
RNAi in the mouse: rapid and affordable gene function studies in a vertebrate system
Rytlewski, J. A., & Beronja, S. (2014) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.164 · Cited by 3
Brain Tumor Models to Predict Clinical Outcome: Like the Phoenix?
Lampson, L. A. (2012) · Neuromethods · doi:10.1007/7657_2011_24 · Cited by 3
The CD95/CD95L Signaling Pathway: A Role in Carcinogenesis
Fouqué, A., & Legembre, P. (2020) · Springer eBooks · doi:10.1007/978-3-030-30845-2_11 · Cited by 4
Death ligand receptor (DLR) signaling: Its non-apoptotic functions in cancer and the consequences of DLR-directed therapies
Rashid, K., Kalthoff, H., Abdulkadir, S. A., & Adam, D. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104299 · Cited by 3
Molecular Targets in Cancer Therapy
Ramteke, A. S., Ramakrishnan, S. K., & Agarwal, R. (2025) · Springer eBooks · doi:10.1007/978-981-96-7336-0 · Cited by 2
Knockdown of IKKβ Inhibits Tumor Development in a Leptomeningeal Metastasis Mouse Model and Proliferation of Lung Cancer Cells
Liu, Y., Li, Y., Li, Z., Li, C., He, J., & Bu, H. (2020) · Cancer Management and Research · doi:10.2147/cmar.s252184 · Cited by 2
New therapeutic avenues in lung cancer based on disturbances in PI3K and RAS pathways
Rosell, R. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70094-6 · Cited by 2
Self-citation
Paradigm shift in cancer treatment: Cancer treatment as a metabolic disease – fusion of Eastern and Western medicine
Hamaguchi, R., & Wada, H. (2017) · Journal of Traditional Chinese Medical Sciences · doi:10.1016/j.jtcms.2017.12.003 · Cited by 2
[Activation of nuclear factor-κB subunit p50/p65 enhances gefitinib resistance of lung adenocarcinoma H1650 cell line].
Pan, Y. H., Huang, S., Wang, X., Gong, W.-X., Liang, C., Du, J.-X., Peng, D.-X., Xie, Y. F., Zheng, L., Zhang, N., et al. (2018) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.1673-4254.2018.05.13 · Cited by 2
Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer
Fennell, D. A., & Swanton, C. (2012) · The EPMA Journal · doi:10.1186/1878-5085-3-6 · Cited by 2
Targeting the reversible drug-tolerant state: aurora kinase A, is that the final answer?
Suda, K. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.05.21 · Cited by 2
Lung adenocarcinoma
Rosell, R. (2012) · doi:10.2217/ebo.12.11 · Cited by 2
Self-citation
Thiostrepton suppresses triple-negative breast cancer through downregulating c-FLIP/SMAD2/3 signaling pathway
Wang, W., Zeng, C.-Y., Shang, Y., Ni, J., Li, G., Li, L.-P., Xi, S.-H., & Chen, S. (2024) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2024.2343420 · Cited by 1
Dual Drug Nanoformulations for Non-Small Cell Lung Cancer Therapeutics: A Systematic Review
Ahmad, F., Tanuja, T., & Raza, K. (2025) · Natural Product Communications · doi:10.1177/1934578x251401396 · Cited by 1
Estrogen Receptor β and Breast Cancer
Thomas, C. G., & Gustafsson, J.-Α. (2018) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-99350-8_12 · Cited by 1
Effect of PAWI-2 on pancreatic cancer stem cell tumors
Cashman, J. R., & Cashman, E. A. (2024) · Investigational New Drugs · doi:10.1007/s10637-024-01447-x · Cited by 1
Targeting the ErbB Family in Head and Neck Cancer
Kiseleva, A. A., Beck, T. N., Serebriiskii, I. G., Liu, H., Burtness, B. A., & Golemis, E. A. (2018) · Current cancer research · doi:10.1007/978-3-319-78762-6_2 · Cited by 1
Can We Optimize the Selection of Patients With Lung Cancer Suitable for EGFR+MET Double Inhibition?
Leonetti, A., Tiseo, M., Rolfo, C. D., Steen, N. V. D., Peters, G. J., & Giovannetti, E. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00180 · Cited by 1
Genetic and Chemical Modifiers of EGFR Dependence in Non-Small Cell Lung Cancer
Sharifnia, T. (2014) · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · Cited by 1
EGFR inhibitors in cancer treatment
Ciardiello, F. (2012) · doi:10.2217/ebo.11.398 · Cited by 1
Improving platinum-based treatments for advanced non-small cell lung cancer
Leung, A. W. Y. (2016) · cIRcle (University of British Columbia) · doi:10.14288/1.0308666 · Cited by 1
Genome-Wide RNA Interference: Functional Genomics in the Postgenomics EraPreprint
Politi, K. A., & Wajapeyee, N. (2017) · Cold Spring Harbor Protocols · doi:10.1101/pdb.top097550 · Cited by 1
Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer
Rosell, R., Aguilar‐Hernández, A., & González‐Cao, M. (2023) · Cancers · doi:10.3390/cancers15092519 · Cited by 1
Self-citation
Identifiying oncogenic drivers in NSCLC cells harboring EGFR kinase domain mutation with resistance to EGFR TKI and mesenchymal phenotype
Gao, Y. (2014)
Inherited and Somatic Genetic factors in Colorectal Cancer Development
Burghel, G. J. (2011) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Discovery of Predictive Biomarkers for Anticancer Drugs
Neve, R. M., Belmont, L. D., Bourgon, R., Evangelista, M., Huang, X., Schmidt, M., Yauch, R. L., & Settleman, J. E. (2013) · Methods and principles in medicinal chemistry · doi:10.1002/9783527677252.ch02
MicroScale: miniaturizing cell arrays for macrogenetic screens
Janakiraman, M., & Solit, D. B. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12003
A Roundup of Articles Published in Recent Months
Subramanian, J., Waqar, S. N., Morgensztern, D., & Govindan, R. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182436098
Mutations block lung-cancer treatment
Ledford, H. K. (2011) · Nature · doi:10.1038/news.2011.178
Promoter Methylation of the CADM1 and 4.1B Genes Occurs Independently of the EGFR or the KRAS2 Mutation in Non-Small Cell Lung Cancer
Kogai, H., Kikuchi, S., Obana, T., Tsuboi, Y., Maruyama, T., Sakurai‐Yageta, M., Asamura, H., Kanai, Y., & Murakami, Y. (2015) · Journal of Cancer Therapy · doi:10.4236/jct.2015.63030
Intervention of non-small cell line cancer oncogenic pathways with delta-tocotrienol
Ji, X. (2012) · Human Biology
Integrative approaches for biological network inferences
Kim, D. (2014) · UTA ResearchCommons (University of Texas Arlington)
Personalized Management of Lung Cancer
Komaki, R. R. (2013) · doi:10.2217/9781780842165
The Small Gtpase Rab35 Is A Novel Oncogenic Regulator Of Pi3K/Akt Signaling
Wheeler, D. B. (2015) · eCommons (Cornell University)
Mechanism of Resistance to Targeted Molecular Therapy
Seike, M. (2017) · Springer eBooks · doi:10.1007/978-981-10-2002-5_13
The Dissection of Signaling Cascades in Neural Stem Cell Proliferation & GBM Promotion
Kusne, Y. N. (2014)
EGFR inhibitors: patient selections and clinical outcome
Rosell, R., & Bonanno, L. (2013) · doi:10.2217/ebo.12.152
Self-citation
MSelection of NSCLC patients to treat with EGFR inhibitors in the era of personalized medicine
Rosell, R., Bonanno, L., & Tarón, M. (2012) · doi:10.2217/ebo.11.46
Self-citation
Non-genetic resistant mechanism to EGFR tyrosine kinase inhibitory therapy
Tan, S. Z. (2015) · TSpace (University of Toronto)
Cancer Stem Cells and Tumor Microenvironment in Radiotherapy
Li, J. J. (2017) · Cancer treatment and research · doi:10.1007/978-3-319-53235-6_9
Atypical Immune Functions of CD95/CD95L
Poissonnier, A., & Legembre, P. (2017) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-56805-8_7
A Meta-analytic Approach for Testing Evolutionary Hypotheses of Acquired Resistance in Metastatic Cancer
Bhardwaj, K. (2014) · uO Research (University of Ottawa) · doi:10.20381/ruor-3562
Cell-cell contact dictates life or death decisions following CD95 activation in cancerPreprint
Balta, G. S. G., Monzel, C., Kleber, S., Beaudouin, J., Kaindl, T., Thiemann, M., Wirtz, C. R., Tanaka, M., & Martín-Villalba, A. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/308346
The mechanisms of acquired resistance to anti-EGFR drugs in non-small cell lung cancer not associated with T790m mutation and their significance in clinical practice
Карабина, Е. В., Lubchenko, L. N., & Давыдов, М. М. (2018) · Advances in molecular oncology · doi:10.17650/2313-805x-2018-5-3-17-24
Receptor do tipo Toll 4 dentre os TLRs de membrana plasmática possui um papel na malignidade de astrocitomas
Moretti, I. F. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2018.tde-05122018-131346
Adaptive Resistance Mechanisms in EGFR Mutant NSCLC
Santarpía, M., Karachaliou, N., Filipska, M., Mayo‐de‐las‐Casas, C., Lazzari, C., González‐Cao, M., & Rosell, R. (2019) · doi:10.1201/9780429275906-12
Self-citation
Overcoming the drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancer cell lines
Liu, Z. (2018) · ThinkTech (Texas Tech University)
Targeted molecular therapy: the cancer paradigm
Davies, D. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-809356-6.00029-0
In vitro and in vivo investigation of the anticancer activity and molecular mechanisms of disulfiram in non-small cell lung cancer
Butcher, K. (2019) · Wolverhampton Intellectual Repository and E-Theses (University of Wolverhampton)
The evolution of views on the possibilities of drug therapy in overcoming acquired resistance not associated with Т790М mutation to anti-EGFR drugs in non-small cell lung cancer
Карабина, Е. В., Lubchenko, L. N., & Garunov, A. N. (2018) · Journal of Modern Oncology · doi:10.26442/1815-1434_2018.3.10-18
MEKANISME CORPORATE GOVERNANCE DAN MANAJEMEN LABA MELALUI MANIPULASI AKTIVITAS RIIL
Aryani, W. D., & Raharja, S. (2011)
Synthetic Lethality and Lung Cancer
Huang, J., Qiao, T., & Wang, X. (2022) · Translational bioinformatics · doi:10.1007/978-981-16-7893-6_5
Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation
Serna‐Blasco, R., Sánchez‐Herrero, E., de Lope, L. R., Sanz‐Moreno, S., Rodríguez-Festa, A., Trotta, D. A., Cruz‐Bermúdez, A., Franco, F., Sánchez-Hernández, A., Campayo, M. D. J., et al. (2022) · Cancers · doi:10.3390/cancers14184446
Benzene fused pyrimidine-based derivatives and their biological properties
Kelm, J. M., Aruri, H., Nyalapatla, P. R., & Gavande, N. S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-443-18616-5.00005-3
[Research Progress on the Combination Therapy of EGFR-TKIs and Metformin in Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer].
Wang, J., Liu, P., Ying, L., Zhu, R., Yang, C., Yang, Y. X., & Su, D. (2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.106.22
Activation of the NF-κB/ALDH1A1 signaling promotes non-mutational resistance to EGFR-TKIs in non-small cell lung cancer
Zhang, L., Weng, G., Liu, C., Li, Q., Li, J., Wang, Y., Huang, C., Lin, W., Zheng, D., & Ye, Y. (2026) · Oncogene · doi:10.1038/s41388-026-03907-5
Signalisation CD95/CD95L : implications dans le Lupus Erythémateux Systémique et développement d'outils thérapeutiques ciblés
Poissonnier, A. (2017) · theses.fr (ABES) · doi:10.70675/6871cec3z4144z4ba0zada3z470b3091446c
Transport ionique dans les neuropathies périphériques induites par les agents anticancéreux : compréhension et atténuation des effets secondaires induits par la chimiothérapie cytotoxique
Cophignon, A. (2018) · theses.fr (ABES) · doi:10.70675/5b1aceaezfbb6z4022za439zfbb970622947
Importance of AJ and cell polarity in the regulation of Fas signaling
Awina, H. (2019) · theses.fr (ABES) · doi:10.70675/7b0a762dzd645z4e23z9222z2abee196c637
Etude de la voie non-apoptotique de CD95 et de l’implication du facteur d’initiation de la traduction eIF4A1
THOMAS, M. L. (2018) · theses.fr (ABES) · doi:10.70675/823b99a7za117z4efaz80d3zab5f82a8327c
Compréhension des étapes précoces de la résistance adaptative aux inhibiteurs de tyrosine kinase de l'EGFR dans les cancers bronchiques
Figarol, S. (2020) · theses.fr (ABES) · doi:10.70675/9b097a88z7be2z4f00z913fze60d534fa601
The role of O-GlcNAcylation in the pathophysiology of Systemic Lupus Erythematosus
Galli, G. (2022) · theses.fr (ABES) · doi:10.70675/db863337z7c69z4a5dz9e94z7163b54542ee
Phase Ib of repotrectinib plus osimertinib in patients with EGFR–mutated advanced non–small cell lung cancer
Aguilar, A., Cobo, M., Calles, A., Azkárate, A., Gonzalez-Cao, M., Molina‐Vila, M. A., & Rosell, R. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109461
Self-citation
The Effects of CARMA3 Downregulation on Proliferation Migration, and Invasion in Non-Small Cell Lung Cancer
张, 苗. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1682824
Tyrosine Kinase Inhibitors for NSCLC and Chronic Myeloid Leukemia: A Comparative Analysis
Hays, P. V. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1016765
BindingDB Entry 50019244: Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities.
BindingDB (2024) · UC San Diego · doi:10.7270/q26d5zbk
BindingDB Entry 50005373: Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
BindingDB (2020) · UC San Diego · doi:10.7270/q2x351c8
BindingDB Entry 50002905: Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An update of recent medicinal chemistry efforts.
BindingDB (2020) · UC San Diego · doi:10.7270/q25m68cw
BindingDB Entry 7929: Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11.
BindingDB (2017) · UC San Diego · doi:10.7270/q24j0d0b
BindingDB Entry 50049231: First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-¿B Activity As Novel Anticancer Agents.
BindingDB (2019) · UC San Diego · doi:10.7270/q2k35wxp
Substrate specificity of receptor tyrosine kinases is critical for selective signaling
Pineda, M. L. (2012) · Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory)

Authors: Bivona, T. G., Hieronymus, H., Parker, J., Chang, K., Taron, M., Rosell, R., Moonsamy, P., Dahlman, K., Miller, V. A., Costa, C., Hannon, G., & Sawyers, C. L.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Cold Spring Harbor Laboratory (US)
Institut Català d'Oncologia (ES)
Howard Hughes Medical Institute (US)
Corresponding author: Sawyers, Charles L.
ORCID: Bivona, Trever G.
Parker, Joel
Chang, Kenneth
Rosell, Rafael
Moonsamy, Philicia
Dahlman, Kimberly
Miller, Vincent A.
Hannon, Gregory
Sawyers, Charles L.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2011-03
Volume: 471
Issue: 7339
Pages: 523-526
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature09870
PMC: PMC3541675
OpenAlex: W2087955215
Cited by: 396
References: 24
Citations by year: 2026: 5 · 2025: 7 · 2024: 8 · 2023: 14 · 2022: 20 · 2021: 19 · 2020: 17 · 2019: 33 · 2018: 46 · 2017: 38 · 2016: 25 · 2015: 27 · 2014: 37 · 2013: 37 · 2012: 39
FWCI: 37.27
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Howard Hughes Medical Institute
Memorial Sloan-Kettering Cancer Center
National Cancer Institute (P01CA013106)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
Keywords: NF-κB signaling, erlotinib, EGFR tyrosine kinase inhibitors, drug resistance, IκB, c-FLIP, IκB kinase, RNAi screen, lung adenocarcinoma, apoptosis, combination therapy, treatment response biomarkers, non-smoker lung cancer
MeSH terms: Erlotinib Hydrochloride, Dose-Response Relationship, Drug, Humans, Lung Neoplasms, Models, Biological, Mutation, Quinazolines, Signal Transduction, Down-Regulation, NF-kappa B, Genes, erbB-1, Drug Resistance, Neoplasm, fas Receptor, I-kappa B Proteins, RNA Interference, Cell Line, Tumor, Mutant Proteins, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks